(Q38729031)

30 June 2018

title

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia (English)

1 reference

30 June 2018

0 references

1 reference

32

John C Byrd

1 reference

30 June 2018

7

Nyla A Heerema

1 reference

30 June 2018

Kristie A Blum

28

Kristie A Blum

1 reference

30 June 2018

Jeffrey A Jones

21

Jeffrey A Jones

1 reference

30 June 2018

Michael R Grever

29

Michael R Grever

1 reference

30 June 2018

Samantha M Jaglowski

25

Samantha Jaglowski

1 reference

30 June 2018

Jennifer A Woyach

1

Jennifer A Woyach

1 reference

30 June 2018

Leslie A Andritsos

26

Leslie A Andritsos

1 reference

30 June 2018

Lynne V Abruzzo

11

Lynne Abruzzo

1 reference

30 June 2018

Farrukh T Awan

27

Farrukh T Awan

1 reference

30 June 2018

James S Blachly

5

James S Blachly

1 reference

30 June 2018

Gerard Lozanski

30

Gerard Lozanski

1 reference

30 June 2018

Arletta Lozanski

6

Arletta Lozanski

1 reference

30 June 2018

Weiqiang Zhao

8

Weiqiang Zhao

1 reference

30 June 2018

Kami Maddocks

23

Kami Maddocks

1 reference

30 June 2018

Amy S Ruppert

2

Amy S Ruppert

1 reference

30 June 2018

Melanie L Davis

16

Melanie Davis

1 reference

30 June 2018

Rose Mantel

13

Rose Mantel

1 reference

30 June 2018

Amy Lehman

4

Amy Lehman

1 reference

30 June 2018

Kerry Rogers

24

Kerry Rogers

1 reference

30 June 2018

author name string

Daphne Guinn

3

1 reference

30 June 2018

Joshua Coleman

9

1 reference

30 June 2018

Daniel Jones

10

1 reference

30 June 2018

Amber Gordon

12

1 reference

30 June 2018

Lisa L Smith

14

1 reference

30 June 2018

Samantha McWhorter

15

1 reference

30 June 2018

Tzyy-Jye Doong

17

1 reference

30 June 2018

Fan Ny

18

1 reference

30 June 2018

Margaret Lucas

19

1 reference

30 June 2018

Weihong Chase

20

1 reference

30 June 2018

Joseph M Flynn

22

1 reference

30 June 2018

Amy J Johnson

31

1 reference

30 June 2018

language of work or name

English

0 references

publication date

13 February 2017

1 reference

30 June 2018

Journal of Clinical Oncology

published in

1 reference

30 June 2018

volume

35

1 reference

30 June 2018

issue

13

1 reference

30 June 2018

page(s)

1437-1443

1 reference

30 June 2018

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Ibrutinib resistance in chronic lymphocytic leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5455463

3 July 2018

Identifiers

DOI

10.1200/JCO.2016.70.2282

1 reference

30 June 2018

PMCID

5455463

1 reference

30 June 2018

PubMed ID

28418267

1 reference

30 June 2018